Apogee Therapeutics 주식 (NASDAQ: APGE)

에 대한 최신 뉴스 Apogee Therapeutics (NASDAQ:APGE) 주식

Apogee Therapeutics

Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

QuantumScape QS Stock

Equities

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

LNTH

PLUG

SMMT

XPEV

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 퀀텀스케이프(NYSE:QS)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 전고체 배터리 산업화 계약을 체결했다고 발표한 후 64.34% 급등했다.

샤오펑 및 퀀텀스케이프는 지난주 최고 성과를 보여준 11개 중형주 중 일부(7월 7일-7월 13일)

Apogee Therapeutics Inc

Macro Economic Events

Global

Economics

Watching Shares Of Companies In Spain; Reuters Reports Spanish PM Sanchez Addressed The Nation On Power Outages, Says No Conclusive Information On Causes Of Blackout

Ant Group&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/alipay" rel="noreferrer noopener">mobile payment platform</a>, Alipay, reported 100 million users for its tap-and-pay service, launched on June 7, 2024.
The service is available in over 400 mainland Chinese cities and supports over 5,000 shopping brands.
Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) introduced the cashless society to China with Alipay&#8217;s QR code and facial recognition function to facilitate payments, similar to Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) Apple Pay, SCMP <a target="_blank" href="https://www.scmp.com/tech/big-tech/article/3307968/alipay-leads-chinas-payments-apps-tap-and-pay-service-amassing-100-million-users" rel="noreferrer noopener">reported</a> last Friday.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44871845/paypal-and-bill-holdings-downgraded-by-analyst-amid-rising-tariffs-and-slower-growth-expectations" rel="noreferrer noopener">PayPal, Bill Holdings Downgraded As Analyst &#8216;Loses Confidence&#8217;</a>
Alibaba and Ant Group founder Jack Ma expressed his conviction in the next two decades of Ant at the 20th anniversary of Alipay in December.
Ant Group boosted its global presence through its digital platform, Alipay+.&nbsp;
Ant&#8217;s early global strategy, <a target="_blank" href="https://www.benzinga.com/news/24/05/38641032/jack-ma-backed-ant-groups-alipay-broadens-payment-reach-across-continents-how-its-shaping-global-com" rel="noreferrer noopener">focused on Southeast Asia</a>, saw investments in Singapore&#8217;s 2C2P and South Korea&#8217;s Kakao Pay, which now facilitate their international growth.&nbsp;The company also expanded into emerging markets like Sri Lanka and Cambodia.
It established European partnerships, such as with Italy&#8217;s Tinaba and Nexi, and in the Middle East through Dubai Duty Free. They are focused on large tourism markets like Japan, Thailand, and Singapore while targeting European, Latin American, and Middle Eastern regions to continue growing their merchant coverage.
Prior reports indicated&nbsp;that Mastercard Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) would enhance its&nbsp;cross-border remittance capabilities by partnering with Alipay. Separately, Ant Group tapped Shanghai Fudan Microelectronics to develop integrated circuits for the service.
On Friday, the companies announced a new chip compatible with every smartphone and can work in extreme temperatures from minus 40 to 85 degrees Celsius. Ant Group has placed orders for over 10 million units, with commercialization by the second half of 2025.
Ant Group initiated a global recruitment plan to work on potential breakthroughs in artificial general intelligence (AGI) and next-generation fundamental models.
Ma <a target="_blank" href="https://www.benzinga.com/25/04/44745275/alibaba-bets-big-on-ai-with-new-cloud-tools-as-jack-ma-reemerges-in-company-comeback" rel="noreferrer noopener">relinquished his corporate</a> roles and maintained a low profile since Chinese regulators scrapped Ant Group&#8217;s initial public offering and initiated an antitrust crackdown on domestic giants, including Alibaba. However, he remains a shareholder.
Lately, Ma has frequently appeared at Alibaba offices as the Chinese e-commerce juggernaut eyes a turnaround and aspires to evolve into an AI powerhouse.
At Alipay&#8217;s 20th anniversary in December 2024, Ma emphasized the importance of AI. Ma also attended the symposium chaired by President Xi Jinping in Beijing.
Price Action:&nbsp;BABA stock is down 2.07% at $117.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/asia/25/04/45015548/baidu-goes-aggressive-chinas-in-ai-price-war-with-alibaba-deepseek" target="_blank" rel="noreferrer noopener">Baidu Goes Aggressive China&#8217;s In AI Price War With Alibaba, DeepSeek</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Asia

Fintech news covering the emerging Financial Technology services sector

Fintech

Emerging Markets

Tech

Media

AAPL

BABA

Ant Group's Alipay Hits 100 Million Users, Unveils New Chip To Power Fintech Expansion

Keefe, Bruyette &amp; Woods analyst Jade Rahmani maintains Meritage Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTH#NYSE">MTH</a>) with a Market Perform and lowers the price target from $90 to $77.

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Maintains Market Perform on Meritage Homes, Lowers Price Target to $77

RBC Capital analyst Brad Heffern maintains Gaming and Leisure Props (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPI#NASDAQ">GLPI</a>) with a Outperform and lowers the price target from $56 to $54.

GLPI

RBC Capital Maintains Outperform on Gaming and Leisure Props, Lowers Price Target to $54

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains MidWestOne Financial Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOFG#NASDAQ">MOFG</a>) with a Outperform and lowers the price target from $39 to $38.

MOFG

Keefe, Bruyette & Woods Maintains Outperform on MidWestOne Financial Gr, Lowers Price Target to $38

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains Lakeland Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKFN#NASDAQ">LKFN</a>) with a Market Perform and lowers the price target from $69 to $65.

LKFN

Keefe, Bruyette & Woods Maintains Market Perform on Lakeland Financial, Lowers Price Target to $65

Palantir Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) shares are pulling back during Monday&#8217;s session by 2.74% to $109.52 after the stock gained some 20% over the past week. The recent rally was fueled by a combination of favorable geopolitical developments, major defense partnerships and strengthening technical signals.
What To Know: Palantir recently broke through a <a href="https://www.benzinga.com/25/04/44985750/stock-of-the-day-is-the-palantir-breakout-finally-here">key resistance level</a> near $97.75, reinforcing the stock's momentum and hinting at the potential for a continued uptrend. The broader market rebound, following <a href="https://www.benzinga.com/25/04/44940900/us-futures-dollar-jump-amid-trumps-latest-comments-on-fed-nikkei-rebounds-to-three-week-high">recent comments</a> from President Donald Trump regarding Federal Reserve leadership, has also provided a supportive backdrop.
Palantir's gains are also being driven by its <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44960295/palantir-shares-climb-after-northrop-grumman-collab-teased-on-x">expanding role</a> in the defense and government technology sectors. The company&#8217;s recently announced partnership with Northrop Grumman on the U.S. Army&#8217;s Tactical Intelligence Targeting Access Node (TITAN) program marks a significant evolution from its traditional software-focused model.
Read Also: <a href="https://www.benzinga.com/trading-ideas/25/04/45020756/trade-deal-or-no-these-2-stocks-will-outperform">Trade Deal Or No, These 2 Stocks Will Outperform</a>
TITAN, a mobile battlefield intelligence platform integrating Palantir's AI with advanced defense hardware, saw its first units delivered to the Army earlier this year.
Additionally, Palantir <a href="https://www.benzinga.com/government/regulations/25/04/44972877/palantir-teams-up-with-google-to-supercharge-fedstart-bringing-ai-tools-to-us-government-agencies-on-secure-cloud">recently announced</a> a collaboration with Google Public Sector to bolster cloud security compliance for federal agencies via its FedStart platform, further cementing its position in defense tech.
Investors are now turning their attention to Palantir's <a href="https://www.benzinga.com/quote/PLTR/earnings">upcoming earnings report</a>, set for May 5. Analyst consensus estimates project EPS of 11 cents on revenue of approximately $799.36 million.
Read Also: <a href="https://www.benzinga.com/news/global/25/04/45038430/massive-power-outages-hit-spain-portugal-snarling-travel-investigations-into-cause-underway">Massive Power Outages Hit Spain, Portugal Snarling Travel: Investigations Into Cause Underway</a>
<h2 class="wp-block-heading">How To Buy PLTR Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Palantir Technologies&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PLTR has a 52-week high of $125.41 and a 52-week low of $20.50.

PLTR

Palantir Stock Is Pulling Back After Rallying 20% Over The Past Week: What's Going On?

RBC Capital analyst Jon Arfstrom maintains First Financial Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFBC#NASDAQ">FFBC</a>) with a Sector Perform and lowers the price target from $30 to $27.

FFBC

RBC Capital Maintains Sector Perform on First Financial Bancorp, Lowers Price Target to $27

Sabre Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) announced Monday that it will <a href="https://www.benzinga.com/pressreleases/25/04/n45037538/sabre-enters-into-definitive-agreement-to-sell-its-hospitality-solutions-business-unit-to-tpg-for-" target="_blank" rel="noreferrer noopener">sell its Hospitality Solutions business</a> to TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) for $1.1 billion in cash. 
This strategic move aims to streamline operations and sharpen the company&#8217;s focus on core technology platforms.
Sabre expects to receive approximately $960 million in net proceeds after taxes and fees, which it intends to use primarily to reduce debt and strengthen its capital structure.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44634677/goldman-sachs-sees-broad-eps-pressure-across-capital-markets-highlights-brookfield-as-a-standout" target="_blank" rel="noreferrer noopener">Goldman Sachs Sees Broad EPS Pressure Across Capital Markets, Highlights Brookfield As A Standout</a>
Sabre CEO Kurt Ekert praised the team behind Hospitality Solutions for their transformation efforts, adding that the divestiture enables Sabre to concentrate more effectively on its airline IT and travel marketplace operations.
Meanwhile, TPG executives Tim Millikin and Paul Hackwell highlighted their commitment to helping the platform expand and adapt to the evolving needs of the hospitality industry.
Hospitality Solutions, built around Sabre's 2005 acquisition of SynXis, supports over 40% of the world's major hotel brands through its reservation and guest management SaaS platform. The business has steadily expanded, offering products like Retail Studio to help hotels better serve customers.
TPG, known for backing tech carveouts such as Boomi and McAfee, will invest in Hospitality Solutions through TPG Capital. Following the deal's close, expected by the late third quarter of 2025, Sabre will provide temporary transition services to ensure operational continuity during the handover.
TPG held cash and cash equivalents of <a href="https://shareholders.tpg.com/static-files/6b2b43d8-0f5f-4fcc-a9d6-58a2eed31a89" target="_blank" rel="noreferrer noopener">$808.02 million</a> as of Dec. 31, 2024.
Price Action: SABR shares are trading higher by 25.11% at $2.74, and TPG is higher by 0.80% at $46.91 at the last check Monday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/25/04/45020756/trade-deal-or-no-these-2-stocks-will-outperform">Trade Deal Or No, These 2 Stocks Will Outperform</a></li>
</ul>
Image: Shutterstock

BKNG

CIBR

EXPE

SABR

Sabre Divests Hospitality Arm To TPG For $1.1B, Plans Debt Reduction

Mastercard Announces End-to-End Solutions For Stablecoin Transactions, From Wallets to Checkouts

Keefe, Bruyette &amp; Woods maintains HomeTrust Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTB#NYSE">HTB</a>) with a Outperform and lowers the price target from $43 to $42.

Keefe, Bruyette & Woods Maintains Outperform on HomeTrust Bancshares, Lowers Price Target to $42

RBC Capital analyst Ben Hendrix maintains Encompass Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHC#NYSE">EHC</a>) with a Outperform and raises the price target from $110 to $125.

RBC Capital Maintains Outperform on Encompass Health, Raises Price Target to $125

Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Corning will report an earnings per share (EPS) of $0.51. 
Anticipation surrounds Corning's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 0.38% increase in the share price the next day.
Here's a look at Corning's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.52</td>
<td>0.46</td>
<td>0.35</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.54</td>
<td>0.47</td>
<td>0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856199_0.png" alt="eps graph" />
<h3>Corning Share Price Analysis</h3>
Shares of Corning were trading at $44.18 as of April 25. Over the last 52-week period, shares are up 31.28%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Corning</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Corning.
The consensus rating for Corning is Buy, based on 5 analyst ratings. With an average one-year price target of $56.0, there's a potential 26.75% upside.
<h3>Analyzing Ratings Among Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Coherent, Littelfuse and Belden, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Coherent, with an average 1-year price target of $100.85, suggesting a potential 128.27% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Littelfuse, with an average 1-year price target of $236.0, suggesting a potential 434.18% upside.</li>
<li>Analysts currently favor an Buy trajectory for Belden, with an average 1-year price target of $127.0, suggesting a potential 187.46% upside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for Coherent, Littelfuse and Belden, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corning</td>
<td>Buy</td>
<td>16.93%</td>
<td>$1.20B</td>
<td>2.85%</td>
</tr>
<tr>
<td>Coherent</td>
<td>Buy</td>
<td>26.80%</td>
<td>$509.35M</td>
<td>1.33%</td>
</tr>
<tr>
<td>Littelfuse</td>
<td>Neutral</td>
<td>-0.81%</td>
<td>$176.84M</td>
<td>-2.08%</td>
</tr>
<tr>
<td>Belden</td>
<td>Buy</td>
<td>20.83%</td>
<td>$249.82M</td>
<td>4.62%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Corning ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. Corning is at the top for Return on Equity.
<h3>All You Need to Know About Corning</h3>
Corning is a leader in materials science, specializing in the production of glass, ceramics, and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
<h3>Corning: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Corning showcased positive performance, achieving a revenue growth rate of 16.93% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 8.85%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.85%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Corning's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.11% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.76, caution is advised due to increased financial risk.
<a href="https://www.benzinga.com/quote/GLW/earnings">To track all earnings releases for Corning visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

What to Expect from Corning's Earnings

Biotech

SOPH

Sophia Genetics Expands Collaboration With AstraZeneca To Accelerate The Deployment Of MSK-ACCESS Powered With SOPHiA DDM Globally

Logitech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Logitech International will report an earnings per share (EPS) of $0.86. 
Investors in Logitech International are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.23, leading to a 4.12% increase in the share price on the subsequent day.
Here's a look at Logitech International's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2025</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.36</td>
<td>0.99</td>
<td>0.86</td>
<td>0.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.59</td>
<td>1.20</td>
<td>1.13</td>
<td>0.99</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-9.0%</td>
<td>-3.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856187_0.png" alt="eps graph" />
<h3>Tracking Logitech International's Stock Performance</h3>
Shares of Logitech International were trading at $77.785 as of April 25. Over the last 52-week period, shares are down 0.8%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/LOGI/earnings">To track all earnings releases for Logitech International visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LOGI

A Look at Logitech International's Upcoming Earnings Report

In 1976, The Wall Street Journal published an opinion column that ascribed an astounding revelation to one of the greatest minds in history. Albert Einstein was asked what he surmised to be man's greatest invention.
He didn't answer with the wheel or electricity. He replied: "Compound interest."
Whether he actually said that is up for debate, but the truth behind the quote is undeniable.
It sounds simple. It is simple. But most investors still get it wrong.
Compounding, Part 1: Interest on your interest
Compound interest is money's version of a perpetual motion machine. You earn interest not just on your principal, but on your interest. And then interest on that. Over and over.
It's how a modest investment return can snowball a portfolio into something impressive—if you let it.
But here's where many investors trip: they become obsessed with chasing higher returns.
Beating the market feels like winning. But building wealth isn't about winning annual benchmark comparisons. Given your risk tolerance and emotional fortitude, it's about growing your portfolio to its maximum potential.
Ask yourself: Would you rather beat the market in some years and end up with $1 million…or underperform in many years but wind up with $1.2 million?
You can't spend bragging rights in retirement.
Compounding, Part 2: Time—the hidden superpower
The longer your money stays invested, the harder compounding works as your silent partner in wealth creation.
Warren Buffett is unquestionably a skilled investor, but his superpower is time. He has been a good investor, a patient investor, for eight decades.
The time component of compounding is the rocket fuel that took Buffett's wealth accumulation into the stratosphere. It's why his first billion came after age 55, and 97% of his wealth came after his 65th birthday.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="1024" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-1024x1024.jpg" alt="" class="wp-image-11698" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-1024x1024.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-300x300.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-150x150.jpg 150w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2-768x768.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/28111600/Warren-Buffett-Net-Worth-version-2.jpg 1080w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Charlie Munger put it bluntly: "The first rule of compounding is to never interrupt it unnecessarily." And how do investors usually interrupt it? By chasing higher returns. That's like taking a chainsaw to a bonsai tree because it's growing too slow.
Peter Lynch ran Fidelity's Magellan Fund from 1977 to 1990, posting an incredible 29.2% average annual return—nearly double the S&amp;P 500. You'd think investors would've made a fortune, right?
Nope. During that remarkable run under Lynch, the average investor in the fund reportedly lost money. Why? They bought in late after big run-ups, panic-sold after downturns, and sat in cash looking for a different "market winner" when they should have stayed the course.
They turned a compounding machine into a vending machine, and it ate their dollar bills. (The Magellan story is not an isolated tale. See <a href="https://cosmodestefano.substack.com/p/winning-the-long-game-investing-requires">here</a> for more on the prevalence of this investor performance gap.)
Compounding, Part 3: New money—the force multiplier
The most underrated lever in wealth-building isn't returns or timing. It's you. Specifically, your monthly contributions.
Let's say you start with $1,000 and earn 10% annually. After five years, you'll have a little over $1,600. Not bad.
But now imagine you also invest $100 every month. After those five years, your portfolio swells to nearly $10,000. That's a 500% leap — not from better performance, but from steady, boring, powerful consistency.
In the first 10-15 years of your wealth-building journey, how much you invest matters more than how well you invest.
But what if you could double your return? Here's how the math shakes out:
<ul>
<li>Save 20% of your salary and earn 5% annually, and your portfolio balance surpasses your salary in about 4.5 years.</li>
<li>Double your return to 10%? You get there just five months faster.</li>
</ul>
The early innings aren't won by clever trades or market timing. They're won by habit and hustle—those monthly contributions. (Later, once your portfolio has real weight behind it, returns start pulling more of the load.)
The wealth accumulation trifecta
Intuitively, pursuing the highest returns feels like the best way to maximize wealth. However, once investors consider the importance of both time and monthly contributions, they realize that maximizing annual returns and maximizing wealth are two different concepts.
To build wealth, you don't need to swing for the fences. You need to stack three simple habits:
<ol>
<li>Earn reasonable, repeatable returns</li>
<li>Let time do its quiet work, uninterrupted</li>
<li>Keep adding fresh cash every month</li>
</ol>
That's the trifecta. No gimmicks. No get-rich-quick trades. Just boring, beautiful compounding.
Don't let the early years of compounding fool you. They feel slow, almost like nothing's happening. But that's how compounding starts. Quiet. Invisible. Then&#8230;exponential.
Stay patient. Stick to your plan. Trust that compounding portfolio growth does work.
Review your investment strategy this week with these three principles in mind. As the current markets bounce around and headlines scream, lean into discipline, not drama.
While others chase performance like caffeinated cats in a laser pointer factory, you'll quietly build unstoppable momentum.
You don't need to be the first across the wealth accumulation finish line, but by embracing all three components of compounding, you can help ensure that you do indeed cross it.
As always, invest often and wisely. Thank you for reading.
&#x2A;&#x2A;
My book, <a href="https://geni.us/wealthyourwaypb" target="_blank" rel="noreferrer noopener">Wealth Your Way,&nbsp;is available on Amazon</a>, and consider subscribing to <a href="https://cosmodestefano.substack.com/">my free newsletter</a>.
The content is for informational purposes only. It is not intended to be nor should it be construed as legal, tax, investment, financial, or other advice. It is merely my own random thoughts.
<figure class="wp-block-image size-full is-resized"><a href="https://geni.us/wealthyourwaypb"><img loading="lazy" decoding="async" width="472" height="538" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos.jpg" alt="" class="wp-image-9279" style="width:472px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos.jpg 472w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/31105237/WYW-with-2025-IPA-winner-and-store-logos-263x300.jpg 263w" sizes="(max-width: 472px) 100vw, 472px" /></a></figure>
The best way to spread the word about a book you enjoyed is to leave an honest review. Thank you for taking the time to&nbsp;<a href="https://www.amazon.com/review/create-review/?ie=UTF8&amp;channel=glance-detail&amp;asin=B09XP7383J">click here</a>&nbsp;and post your review of&nbsp;Wealth Your Way. Your review will help other readers explore their own path to a richer, happier life!

Long Ideas

Education

Opinion

Stop Chasing Returns. Start Building Wealth.

Laboratory Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Laboratory Corp will report an earnings per share (EPS) of $3.73. 
Anticipation surrounds Laboratory Corp's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 0.59% drop in the share price the following trading session.
Here's a look at Laboratory Corp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.39</td>
<td>3.49</td>
<td>3.78</td>
<td>3.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.45</td>
<td>3.50</td>
<td>3.94</td>
<td>3.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856181_0.png" alt="eps graph" />
<h3>Performance of Laboratory Corp Shares</h3>
Shares of Laboratory Corp were trading at $228.31 as of April 25. Over the last 52-week period, shares are up 13.57%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Laboratory Corp</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Laboratory Corp.
The consensus rating for Laboratory Corp is Buy, derived from 9 analyst ratings. An average one-year price target of $273.0 implies a potential 19.57% upside.
<h3>Peer Ratings Comparison</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Quest Diagnostics, DaVita and Chemed, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Quest Diagnostics, with an average 1-year price target of $183.86, suggesting a potential 19.47% downside.</li>
<li>Analysts currently favor an Neutral trajectory for DaVita, with an average 1-year price target of $169.0, suggesting a potential 25.98% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Chemed, with an average 1-year price target of $670.5, suggesting a potential 193.68% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Quest Diagnostics, DaVita and Chemed, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Labcorp Hldgs</td>
<td>Buy</td>
<td>9.76%</td>
<td>$896.30M</td>
<td>1.77%</td>
</tr>
<tr>
<td>Quest Diagnostics</td>
<td>Neutral</td>
<td>12.09%</td>
<td>$863M</td>
<td>3.20%</td>
</tr>
<tr>
<td>DaVita</td>
<td>Neutral</td>
<td>4.73%</td>
<td>$1.07B</td>
<td>102.13%</td>
</tr>
<tr>
<td>Chemed</td>
<td>Outperform</td>
<td>1.09%</td>
<td>$234.12M</td>
<td>6.24%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Laboratory Corp ranks highest in gross profit among its peers. It is in the middle for consensus rating and revenue growth. However, it has the lowest return on equity compared to the other companies analyzed.
<h3>Get to Know Laboratory Corp Better</h3>
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
<h3>Laboratory Corp's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Laboratory Corp showcased positive performance, achieving a revenue growth rate of 9.76% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Laboratory Corp's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.31% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Laboratory Corp's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.77%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Laboratory Corp's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.78%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Laboratory Corp's debt-to-equity ratio is below the industry average. With a ratio of 0.9, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/LH/earnings">To track all earnings releases for Laboratory Corp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Laboratory Corporation Of America Holdings

Earnings Preview: Laboratory Corp

Ares Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCC#NASDAQ">ARCC</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Ares Capital to report an earnings per share (EPS) of $0.54.
The market awaits Ares Capital's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.03, leading to a 1.6% drop in the share price the following trading session.
Here's a look at Ares Capital's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.58</td>
<td>0.59</td>
<td>0.58</td>
<td>0.60</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.55</td>
<td>0.58</td>
<td>0.61</td>
<td>0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856160_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Ares Capital were trading at $21.11 as of April 25. Over the last 52-week period, shares are up 2.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Views on Ares Capital</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ares Capital.
Ares Capital has received a total of 9 ratings from analysts, with the consensus rating as Outperform. With an average one-year price target of $22.83, the consensus suggests a potential 8.15% upside.
<h3>Peer Ratings Comparison</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Franklin Resources, SEI Investments and T. Rowe Price Group, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Franklin Resources, with an average 1-year price target of $19.62, suggesting a potential 7.06% downside.</li>
<li>Analysts currently favor an Neutral trajectory for SEI Investments, with an average 1-year price target of $83.25, suggesting a potential 294.36% upside.</li>
<li>Analysts currently favor an Neutral trajectory for T. Rowe Price Group, with an average 1-year price target of $96.14, suggesting a potential 355.42% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
The peer analysis summary offers a detailed examination of key metrics for Franklin Resources, SEI Investments and T. Rowe Price Group, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blue Owl Capital</td>
<td>Outperform</td>
<td>27.80%</td>
<td>$336.88M</td>
<td>1.00%</td>
</tr>
<tr>
<td>Franklin Resources</td>
<td>Neutral</td>
<td>13.08%</td>
<td>$1.83B</td>
<td>1.19%</td>
</tr>
<tr>
<td>SEI Investments</td>
<td>Neutral</td>
<td>-1.05%</td>
<td>$297.69M</td>
<td>6.72%</td>
</tr>
<tr>
<td>T. Rowe Price Group</td>
<td>Neutral</td>
<td>11.11%</td>
<td>$947.60M</td>
<td>4.16%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ares Capital ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Return on Equity.
<h3>Discovering Ares Capital: A Closer Look</h3>
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
<h3>Key Indicators: Ares Capital's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Ares Capital's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -11.49%. This indicates a decrease in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 90.84%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Ares Capital's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.73%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Ares Capital's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.29%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ares Capital's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.03.
<a href="https://www.benzinga.com/quote/ARCC/earnings">To track all earnings releases for Ares Capital visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARCC

Uncovering Potential: Ares Capital's Earnings Preview

SoFi Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release.
Analysts are estimating that SoFi Techs will report an earnings per share (EPS) of $0.05.
Anticipation surrounds SoFi Techs's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.01, which was followed by a 0.56% increase in the share price the next day.
Here's a look at SoFi Techs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.04</td>
<td>0.04</td>
<td>0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.05</td>
<td>0.05</td>
<td>0.01</td>
<td>0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>7.000000000000001%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856145_0.png" alt="eps graph" />
<h3>Market Performance of SoFi Techs's Stock</h3>
Shares of SoFi Techs were trading at $12.88 as of April 25. Over the last 52-week period, shares are up 91.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about SoFi Techs</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on SoFi Techs.
The consensus rating for SoFi Techs is Neutral, based on 4 analyst ratings. With an average one-year price target of $15.12, there's a potential 17.39% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
In this comparison, we explore the analyst ratings and average 1-year price targets of Credit Acceptance and Enova International, three prominent industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Credit Acceptance, with an average 1-year price target of $475.0, suggesting a potential 3587.89% upside.</li>
<li>Analysts currently favor an Buy trajectory for Enova International, with an average 1-year price target of $134.5, suggesting a potential 944.25% upside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Credit Acceptance and Enova International, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>FirstCash Hldgs</td>
<td>Outperform</td>
<td>-5.36%</td>
<td>$433.69M</td>
<td>4.07%</td>
</tr>
<tr>
<td>Credit Acceptance</td>
<td>Neutral</td>
<td>14.89%</td>
<td>$351.10M</td>
<td>8.95%</td>
</tr>
<tr>
<td>Enova International</td>
<td>Buy</td>
<td>25.01%</td>
<td>$336.05M</td>
<td>5.36%</td>
</tr>
</tbody>
</table>

Key Takeaway:
SoFi Techs ranks highest in Revenue Growth among its peers, showing strong performance. It also leads in Gross Profit, indicating efficient operations. However, it lags behind in Return on Equity compared to its peers. Overall, SoFi Techs is positioned well in terms of revenue growth and gross profit, but could improve its return on equity to align with industry standards.
<h3>Get to Know SoFi Techs Better</h3>
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
<h3>Unraveling the Financial Story of SoFi Techs</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: SoFi Techs's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 22.19%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: SoFi Techs's net margin excels beyond industry benchmarks, reaching 45.29%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): SoFi Techs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.26%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): SoFi Techs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.94%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.49.
<a href="https://www.benzinga.com/quote/SOFI/earnings">To track all earnings releases for SoFi Techs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SOFI

SoFi Techs's Earnings: A Preview

Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Kraft Heinz to report an earnings per share (EPS) of $0.60.
The market awaits Kraft Heinz's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 2.2% increase in the share price the following trading session.
Here's a look at Kraft Heinz's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.78</td>
<td>0.74</td>
<td>0.74</td>
<td>0.69</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.84</td>
<td>0.75</td>
<td>0.78</td>
<td>0.69</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745856134_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Kraft Heinz were trading at $29.49 as of April 25. Over the last 52-week period, shares are down 24.67%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analyst Insights on Kraft Heinz</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Kraft Heinz.
The consensus rating for Kraft Heinz is Neutral, derived from 13 analyst ratings. An average one-year price target of $29.77 implies a potential 0.95% upside.
<h3>Comparing Ratings with Peers</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of Hershey, General Mills and Tyson Foods, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Hershey, with an average 1-year price target of $159.36, suggesting a potential 440.39% upside.</li>
<li>Analysts currently favor an Neutral trajectory for General Mills, with an average 1-year price target of $62.25, suggesting a potential 111.09% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Tyson Foods, with an average 1-year price target of $60.33, suggesting a potential 104.58% upside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Hershey, General Mills and Tyson Foods are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kraft Heinz</td>
<td>Neutral</td>
<td>-4.14%</td>
<td>$2.25B</td>
<td>4.37%</td>
</tr>
<tr>
<td>Hershey</td>
<td>Neutral</td>
<td>8.67%</td>
<td>$1.56B</td>
<td>17.86%</td>
</tr>
<tr>
<td>General Mills</td>
<td>Neutral</td>
<td>-5.04%</td>
<td>$1.64B</td>
<td>6.78%</td>
</tr>
<tr>
<td>Tyson Foods</td>
<td>Neutral</td>
<td>2.28%</td>
<td>$1.09B</td>
<td>1.95%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Kraft Heinz ranks at the bottom for Revenue Growth and Gross Profit, while it is in the middle for Return on Equity.
<h3>Delving into Kraft Heinz's Background</h3>
In July 2015, Kraft merged with Heinz to create one of North America's largest food and beverage manufacturers. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. While the retail channel drives around 85% of its total sales, the firm also maintains a growing foodservice presence. Outside North America, Kraft Heinz's global reach counts a distribution network in Europe and emerging markets that drives nearly 25% of its consolidated sales base, as its products are sold in more than 190 countries and territories.
<h3>Key Indicators: Kraft Heinz's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3 months period, Kraft Heinz faced challenges, resulting in a decline of approximately -4.14% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.
Net Margin: Kraft Heinz's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 32.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Kraft Heinz's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.37%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Kraft Heinz's ROA stands out, surpassing industry averages. With an impressive ROA of 2.41%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Kraft Heinz's debt-to-equity ratio is below the industry average at 0.4, reflecting a lower dependency on debt financing and a more conservative financial approach.
<a href="https://www.benzinga.com/quote/KHC/earnings">To track all earnings releases for Kraft Heinz visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Kraft Heinz's Earnings: A Preview

Health Care

Press Releases

Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024

Apogee Therapeutics Announces Agenda for Virtual R&D Day

Apogee Therapeutics Highlights Progress and Best-in-Class Potential of Novel Biologic Programs for I&I Diseases at 2024 Inaugural R&D Day

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions

Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference

Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis

Apogee Therapeutics to Participate in Upcoming March Investor Conferences

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination Strategy Update on March 3, 2025

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

Galapagos NV - American Depositary Shares

Galapagos

ImmunityBio

Immunovant

Janux Therapeutics

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Citigroup

Wedbush

Canaccord Genuity

B of A Securities

Jefferies

다음은 지난주 큰 폭의 상승세를 보인 11개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요?
<ol>
<li>퀀텀스케이프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>)의 주가는 회사가 폭스바겐(Volkswagen)의 배터리 회사인 파워코(PowerCo)와 <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">전고체 배터리 산업화</a> 계약을 체결했다고 발표한 후 64.34% 급등했다.</li>
<li>랜티우스 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>)의 주가는 전문 <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">진단 방사성 의약품</a>에 대한 지불 개선을 위한 CMS 제안 이후 55.93% 급등했다.</li>
<li>선런(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>)의 주가는 37.59% 상승했다. 최근 CPI 데이터에 따라 더 넓은 산업 분야의 기업 주가가 상승했기 때문이다.</li>
<li>키메라 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>)의 주가는 화농한선염과 아토피성 피부염에 대한 임상 2상을 확대해 <a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener">안전성 및 유효성</a>에 대한 중간 검토를 거쳐 중추적 연구로 보다 신속하게 진행하겠다는 의사를 밝힌 뒤 37.38% 상승했다.</li>
<li>아포지 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>)의 주식은 35.68% 급등했다.</li>
<li>조비 항공(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>)은 회사가 <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">물을 유일한 부산물</a>로 사용하여 523마일을 수소 전기 항공 택시 시연차로 성공적으로 비행했다고 발표한 후 주가는 29.10% 상승했다.</li>
<li>크리네틱스 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>)은 JP모건이 <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 47달러에서 54달러로</a> 상향 조정한 후 주가는 21.18% 상승했다.</li>
<li>다인 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>)은 JP모건이 주식에 대해 비중확대 등급을 유지하고 <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">목표 주가를 39달러에서 43달러로</a> 높인 후 주가는 19.75% 상승했다.</li>
<li>서밋 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>)의 주식은 지난주 17.24% 급등했다.</li>
<li>플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)의 주가는 <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">최근 소비자물가지수(CPI) 발표</a> 이후 전기차 관련주가 상승하면서 16.51% 상승했다. 미국 에너지부는 또한 폐쇄되었거나 위험에 처한 11개의 자동차 시설을 전기 자동차와 공급망 제조를 위해 전환하는 데 17억 달러를 투자한다고 발표했다.</li>
<li>샤오펑(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>)의 주식은 15.56% 상승했다. 6월 중국의 수출이 증가한 것을 계기로 중국 관련 주식이 상승했다.</li>
</ol>
기타 읽어볼 만한 기사:
<ul>
<li><a href="https://kr.benzinga.com/news/%eb%a6%ac%eb%b9%84%ec%95%88%ea%b3%bc-%eb%b0%94%ec%9d%b4%eb%91%90%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ea%b3%a0-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-11%ea%b0%9c%ec%9d%98-%eb%8c%80/" target="_blank" rel="noopener">리비안과 바이두는 지난주 최고 성과를 보인 11개의 대형주 주식 중 일부 (7월 7일-7월 13일)</a></li>
<li><a href="https://kr.benzinga.com/news/%eb%84%b7%ed%94%8c%eb%a6%ad%ec%8a%a4%ec%99%80-%eb%8d%b8%ed%83%80-%ed%95%ad%ea%b3%b5%ec%9d%80-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc%eb%a5%bc-%eb%b3%b4%ec%9d%b8-10/" target="_blank" rel="noopener">넷플릭스와 델타 항공은 지난주 최악의 성과를 보인 10대 대형주 중 일부 (7월 7일-7월 13일)</a></li>
</ul>
Photo Courtesy of QuantumScape
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Apogee Therapeutics

뉴스

에 대한 최신 뉴스 Apogee Therapeutics (NASDAQ:APGE) 주식

월요일, 7월 15, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌